IDH1 and glioblastoma: Further investigation of the location of the IDH1 mutations within the gene using the lollipop module revealed that all mutations occurred at the R132 codon, indicating this is a hotspot mutation (Figure 3D); indeed, it is an established GBM prognostic biomarker and drug target.